Knut Håkon Hole

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer

Harald Bull Ragnum, Ljiljana Vlatkovic, A. Kathrine Lie et al. · British Journal of Cancer · 2014 · 220 citations · Full text

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

Anne Fangberget, Line Brennhaug Nilsen, Knut Håkon Hole et al. · European Radiology · 2010 · 146 citations · Full text

Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy

Tom Børge Johannesen, Hans H. Lien, Knut Håkon Hole et al. · Radiotherapy and Oncology · 2003 · 141 citations

Adaptive Radiotherapy, Neuro-oncology, Radiation Therapy +14

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

Anne Hansen Ree, Svein Dueland, Sigurd Folkvord et al. · The Lancet Oncology · 2010 · 122 citations

Radiation Therapy, Histone Deacetylase Inhibitor, Pelvic Radiation +8

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer

Wolfgang Lilleby, Gustav Gaudernack, Paal Brunsvig et al. · Cancer Immunology Immunotherapy · 2017 · 95 citations · Full text

Vaccination, Urology, Genitourinary Cancer +9